Video course abdominal ultrasound
Examination of the spleen: Anatomy of the spleen
Author: Prof. Dr. Christoph F. Dietrich
©Falk Foundation e.V., Freiburg. All rights reserved.
Please switch on your loudspeakers!
Link to Falk Mediacenter
Latest research in brief:
Colon to Rectum
Text:
Marasco G et al, Gut. 2023;72(3):484–92
Post-COVID-19 irritable bowel syndrome: Hospitalized patients with COVID-19 had fewer problems with constipation and hard stools at 12 months after acute COVID-19 infection. In contrast, patients with COVID-19 had significantly higher rates of irritable bowel syndrome compared to controls.
Link to Falk Mediacenter
Liver and Bile Ducts
Text:
Tsai PC et al, J Hepatol. 2023;78(2):281–92
Metformin reduces risk for hepatocellular carcinoma in individuals with cured chronic hepatitis C and diabetes mellitus: Individuals with diabetes mellitus have a significantly higher risk for hepatocellular carcinoma (HCC) after successful antiviral therapy for hepatitis C. A recent large cohort study from Taiwan suggests that metformin may significantly reduce HCC risk in these individuals.
Link to Falk Mediacenter
Text:
Demory A et al, Hepatology. 2023;77(2):430–42
Body weight change and duration of estrogen exposure modulate evolution of hepatocellular adenomas after discontinuation of contraception: A recent retrospective study indicates that weight reduction leads to regression of liver adenomas. In addition, evolution can be predicted based on the duration of estrogen exposure.
Link to Falk Mediacenter
Text:
Goyal L et al, N Engl J Med. 2023;388(3):228–39
Futibatinib as future treatment candidate for FGFR2-rearranged intrahepatic cholangiocarcinoma: Intrahepatic cholangiocarcinoma still has a very poor prognosis. A recent early clinical study indicates that the FGFR inhibitor futibatinib could be a promising therapy option in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma.
Link to Falk Mediacenter
Esophagus to Small Intestine
Text:
Laine L et al, Gastroenterology. 2023;164(1):61–71
Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: Vonoprazan was non-inferior, but superior to the proton-pump inhibitor lansoprazole in healing and maintenance of healing of erosive esophagitis in a randomized trial. This benefit was seen predominantly in more severe erosive esophagitis.
Link to Falk Mediacenter
Text:
Samadder NJ et al, Gut. 2023;72(2):256–63
Erlotinib to reduce polyp burden associated with familial adenomatous polyposis (FAP): Weekly erlotinib dosing over 6 months resulted in markedly lower duodenal polyp burden and modestly reduced lower gastrointestinal polyp burden after 6 months in a single-arm phase 2 trial.
Link to Falk Mediacenter
Text:
Louis E et al, Lancet Gastroenterol Hepatol. 2023;8(3):215–27
Exit strategies for Crohn’s disease treated with combination therapy with infliximab and immunosuppressant: Results of a randomized trial indicate that patients with Crohn’s disease in sustained steroid-free remission under combination therapy with infliximab and immunosuppressant have an increased risk of disease flares following discontinuation of infliximab. In contrast, de-escalation of immunosuppressant therapy was generally well tolerated and safe.
Link to Falk Mediacenter
Pancreas
Text:
Strickler JH et al, N Engl J Med. 2023;388(1):33–43
Targeted therapy of advanced KRAS p.G12C mutated pancreatic cancer: The KRAS G12C inhibitor sotorasib showed anticancer activity and had an acceptable safety profile in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had received previous chemotherapy.
Link to Falk Mediacenter
Symposium 232
Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?
April 28 – 29, 2023, Bordeaux, France
Program
Online registration
Current Falk literature:
No literature.